Furthermore, the introduction of next-generation TKIs and anti–PD-1/programmed death-ligand 1 (PD-L1) antibodies (a new class of anticancer drugs) was expected to prolong the survival of patients with NSCLC in clinical trials. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.